Drug Prevents Hearing Loss Caused By Brain Tumor Therapy

July 07, 1998

New Study Offers Hope To Cancer Patients

PORTLAND, Ore., July 7, 1998 -- Reporting in the July issue of the Journal of Pharmacology and Experimental Therapeutics, researchers with the Portland U.S. Department of Veterans Affairs Medical Center and Oregon Health Sciences University have found that they can prevent or sharply reduce hearing loss caused by one of the most effective therapies for brain tumors.

The VA/OHSU team found that treatment with sodium thiosulfate (STS) significantly reduced hearing loss in 29 brain tumor patients receiving the chemotherapy agent carboplatin delivered by opening the blood-brain barrier.

"These findings are very encouraging," said study leader Edward A. Neuwelt, M.D., a neurosurgeon and professor of neurology and neurosurgery at the Portland VA Medical Center and OHSU. He also directs the Blood-Brain Barrier Program located at both the VA and OHSU.

"Not only did we see fewer patients suffer severe hearing loss, but patients who did experience some hearing loss were able to undergo more courses of carboplatin treatment before any loss occurred."

Before the STS trials began, 15 (79 percent) of 19 similar patients suffered profound hearing loss caused by carboplatin treatment. These patients had an average hearing loss of 20.8 decibels after one treatment with carboplatin, while the STS-treated patients lost only 3.7 decibels.

The Portland researchers previously had paved the way for brain tumor treatment with carboplatin and similar agents by pioneering methods to open the "blood-brain barrier" in order to enhance drug delivery (Neurosurgery, May 1998). This natural barrier normally serves as a wall between the blood and brain, helping protect brain tissue.However, it also prevents large-molecule drugs such as carboplatin from reaching a tumor inside the brain.

Using a sugar solution to temporarily shrink the barrier cells, thereby creating spaces between them, Neuwelt and his colleagues literally "opened the gate" for drugs such as carboplatin to enter the brain.

They subsequently found that carboplatin was one of the most effective therapies for brain tumors (Cancer Journal/Science American, March/April 1998), but it unexpectedly caused major hearing loss when given across an open blood-brain barrier.

Approximately a third to one-half of cancer patients treated with the platinum-based chemotherapy agent cisplatin develop some degree of communication difficulty due to hearing loss, Neuwelt pointed out. The related drug carboplatin, however, previously had caused only modest hearing loss when used to treat patients with cancers in other parts of the body.

"We were surprised to find that our carboplatin-treated patients experienced profound high frequency hearing loss," Neuwelt said.Many of the brain-tumor patients treated with carboplatin prior to the STS trials required hearing aids following their therapy he noted.

"If you're in a quiet room, hearing loss in the high frequency range is not a big problem, but if you have background noise, high frequency hearing loss significantly impairs communication."

After an exhaustive Internet search, the husband of one of Neuwelt's patients suggested that STS might help prevent the hearing loss. The VA/OHSU team eventually confirmed that STS could preserve hearing in animals treated with carboplatin (Cancer Research, February 15, 1996) and proceeded with clinical trials.

Using a "two-compartment system," the researchers first opened the blood-brain barrier, administered carboplatin chemotherapy by artery to attack the patient's brain tumor and then waited two hours before giving intravenous STS.

"You have to open the gate to let the drug in and then wait until the gate is closed to give STS," Neuwelt said. Studies have shown that STS can cause seizures if given to animals when the blood-brain barrier is open.

STS apparently protects hearing by binding to the platinum in carboplatin before it has a chance to harm the inner ears, Neuwelt said.

"The take-home message is that sodium thiosulfate is the first drug shown to prevent chemotherapy-induced hearing loss. These results with STS may prove useful in combating the hearing loss associated with platinum-based chemotherapy treatment for other types of cancer such as cancer of the ovary and lung."

Neuwelt's co-authors of the JPET paper include Robert E.Brummett, Ph.D., Nancy D. Doolittle, Ph.D., Leslie L. Muldoon, Ph.D., Robert A. Kroll, D.V.M., Michael A. Pagel, Rhonda Dojan, Victoria Church, Laura G. Remsen, Ph.D., D.V.M., and Joseph S. Bubalo.

Their work was supported by the Department of Veterans Affairs Merits Review Program and the National Institutes of Health.

VA research provides improved medical center care for veterans, as well as the general population.Through its unique affiliation with medical schools such as OHSU, VA plays a crucial role in educating future physicians in research and clinically oriented areas.

A patient who has undergone blood-brain barrier treatment and who has taken sodium thiosulfate is available for interviews. Please call 503-494-8231 to arrange.
-end-


Oregon Health & Science University

Related Cancer Articles from Brightsurf:

New blood cancer treatment works by selectively interfering with cancer cell signalling
University of Alberta scientists have identified the mechanism of action behind a new type of precision cancer drug for blood cancers that is set for human trials, according to research published in Nature Communications.

UCI researchers uncover cancer cell vulnerabilities; may lead to better cancer therapies
A new University of California, Irvine-led study reveals a protein responsible for genetic changes resulting in a variety of cancers, may also be the key to more effective, targeted cancer therapy.

Breast cancer treatment costs highest among young women with metastic cancer
In a fight for their lives, young women, age 18-44, spend double the amount of older women to survive metastatic breast cancer, according to a large statewide study by the University of North Carolina at Chapel Hill.

Cancer mortality continues steady decline, driven by progress against lung cancer
The cancer death rate declined by 29% from 1991 to 2017, including a 2.2% drop from 2016 to 2017, the largest single-year drop in cancer mortality ever reported.

Stress in cervical cancer patients associated with higher risk of cancer-specific mortality
Psychological stress was associated with a higher risk of cancer-specific mortality in women diagnosed with cervical cancer.

Cancer-sniffing dogs 97% accurate in identifying lung cancer, according to study in JAOA
The next step will be to further fractionate the samples based on chemical and physical properties, presenting them back to the dogs until the specific biomarkers for each cancer are identified.

Moffitt Cancer Center researchers identify one way T cell function may fail in cancer
Moffitt Cancer Center researchers have discovered a mechanism by which one type of immune cell, CD8+ T cells, can become dysfunctional, impeding its ability to seek and kill cancer cells.

More cancer survivors, fewer cancer specialists point to challenge in meeting care needs
An aging population, a growing number of cancer survivors, and a projected shortage of cancer care providers will result in a challenge in delivering the care for cancer survivors in the United States if systemic changes are not made.

New cancer vaccine platform a potential tool for efficacious targeted cancer therapy
Researchers at the University of Helsinki have discovered a solution in the form of a cancer vaccine platform for improving the efficacy of oncolytic viruses used in cancer treatment.

American Cancer Society outlines blueprint for cancer control in the 21st century
The American Cancer Society is outlining its vision for cancer control in the decades ahead in a series of articles that forms the basis of a national cancer control plan.

Read More: Cancer News and Cancer Current Events
Brightsurf.com is a participant in the Amazon Services LLC Associates Program, an affiliate advertising program designed to provide a means for sites to earn advertising fees by advertising and linking to Amazon.com.